The Medical Letter on Drugs and Therapeutics
Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
The full article is available to subscribers Subscriber Login   

The FDA has approved extended-release (ER) calcifediol (25-hydroxyvitamin D3; Rayaldee – Opko), a prohormone of calcitriol, the active form of vitamin D3. It is indicated for treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) who have serum total 25-hydroxyvitamin D levels <30 ng/mL.

TREATMENT OF SHPT — Secondary hyperparathyroidism is a common complication of CKD; it develops in response to declining renal function, impaired phosphate excretion, and the inability of the kidneys to convert vitamin D to calcitriol (1,25-dihydroxyvitamin D3). Reduced synthesis of calcitriol leads to low levels of serum calcium and elevated levels of serum phosphorus, which results in increased parathyroid hormone (PTH) secretion.1

Nutritional (inactive) vitamin D is effective in repleting vitamin D stores, but it ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
Article code: 1515d
 Electronic, downloadable article - $25